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Introduction  
Neurological and endocrine pathologies such as acromegalie, Cushing’s disease, and 
neuropathic pain display disregulated exocytosis. Silencing specific cell populations would 
thus be invaluable to correct these debilitating disorders. To achieve this goal, we re-
engineered the Botulinum neurotoxin (BoT), a highly potent pharmaceutical compound 
capable of inhibiting exocytosis, and fused to it a protein “stapling” domain [1,2]. These 
peptide motifs, that form an irreversible tetrahelical coiled-coil, are able to link a variety of 
targeting domains onto the enzyme and thus redirect it towards normally unaffected cells. 
The conformational diversity of this assembly process greatly supersedes traditional protein 
expression since multiple targeting domains (homo- and hetero-) can be linked onto one 
scaffold, larger yields can be produced separately, it permits the combination of solid-phase 
peptide synthesis with recombinant protein expression, and it can avoid the necessity of an 
N- to C- translational fusion. With only a few dozen building “blocks” it is possible to 
construct thousands of different complexes specifically tailored for each purpose as every 
individual component can be linked onto any other cognate stapling moieties. 
We then assayed a range of targeting domains composed of neuropeptides and factors 
sequences that would exploit each cell’s surface receptor expression (see Figure 1).  
Results and Discussion 
Our results show that Corticotropin Releasing Hormone (CRH), Epidermal growth factor 
(EGF), Ciliary neurotrophic factor (CNTF), Vasoactive Intestinal peptide (VIP), as well as 
others, can potentiate the receptor mediated internalization of the BoT enzyme cargo into 
specific, and pathologically important, cell types [3]. Following this intracellular delivery, 
those cells displayed significant reductions of hormone and neurotransmitter release.  
 
Fig. 1. Schematic representation of SNARE base protein stapling. 
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 Using botulinum neurotoxin’s 
highly sensitive efficacy readout, 
which is the intracellular 
cleavage of SNAP25, we have 
been able to characterize these 
new cargo amenable targeting 
domains. This strategy enabled 
the retargeting of BoNT/A to 
neuroendocrine cells that are 
normally unaffected by the 
native toxin's receptor binding 
domain. These new toxin 
complexes can bind to- and be 
internalized into PC12, 
Neuro2A, SH-SY5Y, AtT20, 
and Min6 cells as well as 
different subpopulations of 
ex-vivo rat cortical cells. Once 
internalized by receptor-medi-
ated endocytosis, the enzyme 
cargo cleaves SNAP25 and thus inhibits exocytosis. Furthermore, the facility at which one 
can recombine the different targeting domains onto the enzymatic cargo permits us to 
explore novel conformations that protein recombination does not permit. As shown in 
Figure 2, using single EGF and CNTF targeting domains, domain on Neuro2A cells permits 
protease entry. However, when they are both included as a hetero bifunctional targeting 
domains onto a single complex, the efficacy of internalization is increased (Figure 2A). Such 
approaches could undoubtedly heighten the cell selectivity to the cargo delivery. While 
testing the corticotroph AtT-20 cells, which are amenable to CRH targeting, we saw that the 
homodimer targeting domains greatly enhanced the cytosolic entry compared to the 
monomer domain (Figure 2B). Such approach enables receptor dimer targeting while also 
elevating the probability of statistical rebinding. The functional targeting domains such as 
EGF, CNTF, CRH, and VIP, identified in this study, can be complexed with other stapled 
domains of diverse utilities (e.g. fluorophores, chelators, reactive groups). Combinations of 
stapled domains enable a “swiss-army knife” configuration to the pharmaceutical molecule. 
Such as ameliorated efficacy through heightened avidity, a strategy that remains intransigent 
for single strand protein expression. This targeted secretion inhibitor assembly platform has 
numerous biotechnological and medical implications [1,3]. Current endeavors are aimed 
towards testing our compounds in animal models, and subsequently, for clinical trials. Future 
work will be directed towards monitoring in vivo activity of our compounds to treat 
endocrinopathies and extend this approach to other pharmaceutically useful cargos.  
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Fig. 2. a) Western immunoblotting of total SNAP25 of 
neuro2A cells. b) Western immunoblotting of total 
SNAP25 in AtT-20cells. 
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